Highlights from ESMO WCGIC 2021: VALENTINO, KEYNOTE-811 & BEACON-CRC

The ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2021 annual meeting took place virtually this year and leading experts came together to present on the most recent developments in GI cancer. In this podcast, Paolo Manca, MD, Istituto Nazionale dei Tumori Milano, Milano, Italy, Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Dan Aderka, MD, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel, discuss results from the VALENTINO (NCT02476045), KEYNOTE-811 (NCT03615326), and BEACON-CRC (NCT02928224) trials. Both the VALENTINO and KEYNOTE-811 trials investigated the use of monoclonal antibodies with chemotherapy in colorectal and gastric cancer respectively, whereas the BEACON-CRC trial assessed the effects of first-line bevacizumab in BRAF V600E-mutant metastatic colorectal cancer. This interview took place at the virtual ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2021 annual meeting.